Riding a ‘Trojan horse’ against cancer

Informations projet

TROJAN

N° de convention de subvention: 956900

DOI

10.3030/956900

Projet clôturé

Date de signature de la CE 20 Juillet 2020

Date de début 1 Janvier 2021

Date de fin 31 Decembre 2022

Financé au titre de

• EXCELLENT SCIENCE - European Research Council (ERC)

Coût total

Aucune donnée

Contribution de l’UE

€ 150 000,00

Coordonné par

SZKOLA GLOWNA GOSPODARSTWA WIEJSKIEGO
Poland

Periodic Reporting for period 1 - TROJAN (Riding a ‘Trojan horse’ against cancer)

Période du rapport: 2021-01-01 au 2022-12-31

Résumé du contexte et des objectifs généraux du projet

Macrophages are continuously recruited into the tumor mass, even to the most hypoxic regions, and therefore represent a promising vehicle to deliver cancer therapeutics into the tumor. The pioneering research of our team demonstrated that macrophages are able to take up ferritins loaded with anti-cancer drugs, creating Macrophage-Drug Conjugates (MDCs). We have demonstrated that MDCs actively migrate to solid tumors, and we have proven that MDCs can be used as a ‘Trojan horse’ to efficiently deliver drugs directly to the cancer cells.

Now we aim to turn the MDC technology into a commercial and social value proposition by translating our findings to more reliable pre-clinical model for further clinical development. This project provide the proof of concept for the efficacy of our innovative MDC technology, and establish the viability, feasibility, commercialization and overall direction for our MDC technology.